Aurobindo Pharma is a Hyderabad headquartered pharmaceutical company that is involved in manufacturing generic Pharma products and active pharmaceutical ingredients. The company claims its major therapeutic areas to be that of cardiovascular products, central nervous system products, anti-retrovirals, antibiotics, anti-allergics and gastroenterologicals. To ensure that its products have global reach, Aurobindo Pharma has tie ups with other Pharma companies like AstraZeneca and Pfizer as part of its enhanced marketing efforts. In the recent past, it has made major strides in the development of new drugs, thus featuring in the list of India’s top 10 companies in the parameter of consolidated revenues. The company launched its manufacturing unit in the year 1988-89 dedicated in the production of Semi-Synthetic Penicillin. In the year 1992, the company came into public and its shares were listed in the Indian Stock Exchanges. Anti-diabetics is also supposed to be their key major therapeutic area.
Aurobindo Pharma grabbed the global limelight when United States Food and Regulatory Authority approved its Paricalcitol capsules and Tranexamic acid injection to be marketed in the country. According to analysts, both the approved products command a market revenue of $50 million. Tranexamic acid injection can be used to control bleeding most experienced by people suffering from hemophilia and those subjected to dental extraction procedures. The dosage strengths of Paricalcitol capsules approved by FDA are 1mg, 2mg and 4mg. These capsules have the potential to treat secondary hyperparathyroidism that is usually observed in people affected of chronic kidney disease.